Title
Suppressed calcineurin-dependent gene expression identifies lung allograft recipients at increased risk of infection.

Permalink
https://escholarship.org/uc/item/7q54f5cs

Authors
Greenland, JR
Chong, T
Wang, AS
et al.

Publication Date
2018-04-19

DOI
10.1111/ajt.14886

License
CC BY-ND 4.0

Peer reviewed
Suppressed calcineurin-dependent gene expression identifies lung allograft recipients at increased risk of infection

John R Greenland, MD, PhD1,2,4, Tiffany Chong, BA2, Angelia S Wang, MPH2, Emily Martinez, MS2, Pavan Shrestha, BS2, Jasleen Kukreja, MD3, Steven R. Hays, MD2, Jeffrey A Golden, MD2,3, Jonathan P Singer, MD, MS2, Qizhi Tang, PhD3

1 Medical Service, Veterans Affairs Health Care System, San Francisco CA, 94121
2 Department of Medicine, University of California, San Francisco CA, 94143
3 Department of Surgery, University of California, San Francisco CA, 94143
4 Corresponding author: john.greenland@ucsf.edu
ClinicalTrials.gov Identifier: NCT02278952

Abbreviations:
AP-1, Activator protein 1; ATP, adenosine triphosphate; BAL, bronchoalveolar lavage; CI, Confidence Interval; CLAD, chronic lung allograft dysfunction; GEE, generalized estimating equations; GM-CSF, Granulocyte-macrophage colony-stimulating factor; IC50, concentration inhibiting 50%; IL-2, Interleukin-2; ISHLT, International Society of Heart and Lung Transplantation; MRE, Mean residual expression of calcineurin-dependent genes; N, Number; NFAT, nuclear factor of activated T-cells; PBMC, peripheral blood mononuclear cell; PCR, Polymerase chain reaction; PMA, phorbol 12-myristate 13-acetate; SD, Standard deviation; TNF-α, Tumor necrosis factor alpha; UCSF, University of California, San Francisco
ABSTRACT:
Lung transplant immunosuppression regimens generally include the calcineurin inhibitor tacrolimus. We hypothesized that mean residual expression (MRE) of calcineurin-dependent genes assesses rejection and infection risk better than tacrolimus trough. We prospectively followed 44 lung allograft recipients 2 to 18 months post-transplant and measured changes in whole blood IL-2, interferon-γ, and GM-CSF gene expression following a tacrolimus dose. Post-transplant duration, immunosuppressive medication levels, and bronchoscopic rejection and infection assessments were compared with MRE using generalized-estimating equation-adjusted models. Prednisolone effect on MRE was assessed ex vivo in blood samples from non-transplanted controls. Tacrolimus concentration inhibiting 50% of cytokine production (IC₅₀) was measured in a pre-transplant subset. Results showed that MRE did not change with diagnosis of rejection, but that airway infection was associated with a 20% absolute decrease (95% CI 11% – 29%). MRE increased with time following transplantation but was not associated with tacrolimus trough. Interestingly, MRE correlated inversely with corticosteroid dose in the study cohort and ex vivo. Pre-transplant tacrolimus IC₅₀ depended on the cytokine measured and varied between individuals, suggesting a range in baseline responses to tacrolimus. We conclude that MRE identifies infection risk in lung allograft recipients, potentially integrating calcineurin inhibitor and steroid effects on lymphocyte effector function.

INTRODUCTION:
Tacrolimus is a critical component of most post-lung transplant maintenance immunosuppression regimens (1). Following initial observations of highly variable efficacy and side-effect profiles with fixed dosing regimens, dosing by trough has become the standard of care (2). However, variation in clinical effects between individuals with similar trough levels has led to the concern that tacrolimus trough levels inaccurately reflect degree of immunosuppression. Several clinical studies have investigated an assay based on the mean residual gene expression (MRE) at peak versus trough calcineurin inhibitor concentrations following a single dose. The three genes assayed are downstream of the nuclear factor of activated T-cells (NFAT) family of transcription factors that are activated by calcineurin, and so this gene expression ratio may assess the degree of immunosuppression attributable to a given dose of calcineurin inhibitor (3, 4). It is hoped that tacrolimus titration based on this assay could lead to decreased incidence of rejection, infection, and cancer in renal allograft recipients (5, 6).
Optimizing immunosuppression in lung allograft recipients remains challenging. In the first-year after transplantation, 35% of lung allograft recipients have at least one episode of acute rejection requiring treatment (7). Acute cellular rejection is a risk factor for chronic lung allograft dysfunction (CLAD), which affects nearly 50% of patients at 5 years and is the most significant cause of death after the first year (7, 8). Acute cellular rejection and CLAD occur despite high doses of tacrolimus combined with mycophenolate mofetil and prednisone. At the same time, these immunosuppression regimens have been linked with increased rates of infection and malignancy (9).

The difficulties tailoring immunosuppressive therapy for lung transplant recipients have fueled demand for a blood-based assay to monitor the immune system. The ImmuKnow assay measures CD4+ T cell production of adenosine triphosphate (ATP) in response to stimulation with phorbol 12-myristate 13-acetate (PMA). However, enthusiasm for this assay diminished after studies demonstrated poor test characteristics for diagnosing infection and rejection in lung transplant recipients (10). The MRE assay is thought to be more specific to tacrolimus because the comparison of peak and trough gene expression can mitigate impacts of peripheral blood mononuclear cell (PBMC) lymphocyte count and of other immunosuppressive medications (11, 12). The use of ionomycin to trigger calcium-dependent NFAT signaling and the measurement of the expression of genes under the NFAT promoter should further enhance the specificity for calcineurin inhibitors.

This MRE assay has shown early success in monitoring kidney, liver, and heart allograft recipients (3, 13, 14). However, the specificity of this assay for tacrolimus dosing and performance characteristics in identifying infection and rejection risk previously has not been evaluated in lung allograft recipients. We hypothesized that MRE levels would be associated with the level of tacrolimus-based immunosuppression and could identify lung transplant recipients at increased risk for infection or rejection.

**MATERIALS AND METHODS:**

**Study population**
This prospective observational cohort study was approved by the University of California, San Francisco (UCSF) institutional review board under protocol #14-13221 and registered on clinicaltrials.gov (identifier NCT02278952). The study was performed in accordance with the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice.
guidelines. Assay optimization and post-hoc analyses were performed on anonymized whole blood samples from healthy, non-transplanted volunteers obtained under protocol #15-16072. Lung transplant recipients at UCSF were recruited 1-2 months after transplantation and followed for 6 to 18 months after transplantation. Subjects not treated with tacrolimus were excluded. All subjects provided written informed consent.

Immunosuppression practices followed institutional protocols. Induction regimens included basiliximab and methylprednisolone. In the absence of rejection, prednisone was administered at 20 mg daily for the first 3 months, tapered to 0.2 mg/kg daily over the next 3 months, and then gradually tapered to 0.1 mg/kg by 12 months. Targeted tacrolimus troughs were 10-14 ng/ml in the first 3 months, 10-12 ng/ml in the next 3 months, and 8-10 ng/ml thereafter. Mycophenolate mofetil was started in the immediate post-operative period targeting 2 g/day in divided doses but could be reduced or stopped in the setting of leukopenia, skin cancer, or other side effects.

**Predictor variables: MRE and flow cytometric assays.**

MRE assays were performed within one day of a bronchoscopy. Briefly, residual expression of IFN-γ, IL-2 and GM-CSF in stimulated whole blood samples taken at 90-120 minutes after a tacrolimus dose versus trough were determined by quantitative PCR, as previously described (3, 4). Detailed descriptions of the MRE assay and of flow cytometric measurement of tacrolimus IC_{50} are contained in the supplement.

**Outcome measures**

Acute cellular rejection and bronchoscopically-detected infection were the primary outcomes. Acute cellular rejection was determined based on clinical interpretation of transbronchial biopsy specimens graded for rejection according to International Society for Heart and Lung Transplantation (ISHLT) guidelines, predominantly by a single thoracic transplant pathologist (15), who was not aware of MRE values. Infection was defined based on the presence of a potentially pathogenic organism in bronchoalveolar lavage (BAL) fluid and one or more of the following: symptoms consistent with acute infection, CT findings suggesting active infection, or moderate or greater organism burden on semi-quantitative culture. This study definition was based on the 2010 ISHLT definitions of pneumonia and trachobronchitis. Since moderate or greater burdens of pathogenic organisms are typically treated with antibiotics per UCSF protocols, we added high organism burden as a criteria (16).
Daily mycophenolate mofetil, prednisone, and tacrolimus doses were abstracted from clinical charts. Tacrolimus troughs were assayed on whole blood by the clinical lab using the Architect Immunoassay (Abbott Park, IL). The tacrolimus trough value closest in time to the study visit was used.

Sample Size and Statistical Analysis
The target enrollment was 50 subjects, which was estimated to provide 97% power to identify subjects at risk for acute cellular rejection and 89% power to identify subjects at risk for infections, assuming a 5% incidence of ≥ A2-grade rejection and an 18% incidence of infection. These power calculations were performed based on two samples t-tests (17) with effective sample sizes adjusted for intracluster correlation (18).

Reproducibility of MRE measurements was determined by Pearson’s product moment correlation. Associations between MRE, weeks after transplantation and tacrolimus trough level were visualized using generalized additive modeling. Associations with infection and rejection status, time post-transplant, and immunosuppressive agent doses and trough levels were tested using separate linear models adjusted with generalized estimating equations (GEE) to account for repeated measures on individual subjects. The local hazard ratios for infection versus MRE and tacrolimus trough level were determined using a logistic generalized additive mixed model, with subject identifier as a random effect and MRE and tacrolimus trough level as a fixed effect. Statistical analyses were performed in R (version 3.3.2, R Foundation for Statistical Computing, Vienna, Austria) using the “pwr,” “gee,” “mgcv,” and “nplr” packages (17, 19, 20).

RESULTS:
Subject characteristics of the included subject population are shown in Table 1. Of enrolled subjects, interstitial lung diseases and double lung transplants are more frequent than in ISHLT registry populations (7). A flow diagram of subject enrollment and study sample collection is shown in the Supplement. There were 117 MRE assessments included on 44 subjects. Of these assessments, 17 were at the time of bronchoscopically-detected infection and 11 were at the time of acute cellular rejection, including two events with concurrent infection and rejection.

To assess MRE assay reproducibility in our laboratory, we compared MRE values determined from a single study visit using two different quantitative PCR devices. After correcting for the
small bias between the two devices described in Supplemental Figure 2, we found a correlation coefficient of 0.98 (95% CI 0.94-0.99) for 17 paired MRE measurements, suggesting high reproducibility. There were no statistically significant associations between MRE and the time intervals between the tacrolimus doses or between tacrolimus dose and peak level blood draw (Supplemental Figure 3).

**Immunosuppression effects on MRE**

MRE is expected to vary inversely with immunosuppression; thus, we predicted that MRE will increase over time post-transplant because of protocoled reductions in tacrolimus trough targets. As shown in Figure 1A, we did observe a positive correlation with time post-transplant, with MRE increasing an average of 0.35% (95% CI 0.001 – 0.69%) per week. While one might expect MRE levels to decrease with increasing trough tacrolimus levels, previous studies showed an association with tacrolimus peak but not with trough levels (6). Similarly, we did not observe a significant association between MRE and tacrolimus trough (P = 0.11, Figure 1B) or daily dose (P = 0.47, not shown). There was also no association between MRE and daily mycophenolate mofetil dose (P = 0.46, Figure 1C). However, MRE decreased 1.7% (95% CI 3.3 – 0.1%) per additional mg of daily prednisone (Figure 1D).

We sought to determine if prednisone could synergize with tacrolimus in repressing NFAT-dependent cytokine signaling, as suggested by Figure 1B. To model this ex vivo, we incubated whole blood from 5 non-transplanted control subjects with variable concentrations of prednisolone and 0 or 10 ng/ml of tacrolimus and calculated the MRE. Oral prednisone is converted into biologically active prednisolone, and transplant recipient plasma prednisolone concentrations are approximately 10 ng/ml per 1 mg of oral prednisone (21). As shown in Figure 2, we found that MRE peaked at the very low prednisolone concentration of 20 ng/ml, which is roughly equivalent to that produced by a 2 mg dose of prednisone. MRE was decreased at prednisolone levels equivalent to those seen in our study cohort of 100 and 200 ng/ml, corresponding to prednisone doses of 10 and 20 mg, respectively, compared with 0 or 20 ng/ml of prednisolone (P ≤ 0.005). The effect of prednisone on each gene was similar in both the cohort and ex vivo studies.

**Association between MRE and primary outcomes**

Our primary aim was to assess for an association between MRE and acute cellular rejection and bronchoscopically-detected infection, analogous to what has been seen in the context of other
solid organ transplants. As shown in Figure 3A, we did not observe differences in the distribution of MRE when transbronchial biopsies showed acute cellular rejection pathology as compared with biopsies showing no rejection (P = 0.74). However, we did observe significantly lower MRE during infection compared with no infection, with a difference in means of 20% (95% CI 11% – 29%, P < 0.001, Figure 3B). This difference remained when time post-transplant, tacrolimus trough, and prednisone dose were included in the GEE-adjusted model (β = 19%, 95% CI 9% – 29%, P < 0.001). Interestingly, subjects with concurrent rejection and infection at the time of MRE analysis had some of the lowest MRE values. We compared tacrolimus trough and MRE for an association with bronchoscopically-detected infection risk by multivariable modeling (Figure 3C-D), finding MRE to be superior to tacrolimus trough in assessing infection risk. The hazard ratio for infection per 10% increase in MRE was 0.75 (95% CI 0.63 – 0.90, P = 0.001), while there was no statistically significant association between tacrolimus trough and infection risk (HR 1.06, 95% CI 0.85 – 1.31, P = 0.62). There were no statistically significant interactions between week after transplant, infection, and prednisolone dose when these terms considered in pairwise manner in association with MRE. However, a trend towards a negative interaction between week post-transplant and infection (P = 0.06) suggests that MRE might be lower in late infections. The hazard for infection appeared linear over a range of MRE values (Figure 3D). Of the three cytokines that make up the MRE value, IL-2 had the strongest association with infection risk.

**Pre-transplant tacrolimus IC<sub>50</sub>**

We sought to determine the extent to which intrinsic subject characteristics contributed to the variability in immunosuppression as measured by MRE. In a post hoc analysis, we determined tacrolimus IC<sub>50</sub> values using flow cytometry for 21 of the subjects in our study for whom pre-transplant PBMC samples were available. In addition to the IL-2 and interferon-γ cytokine production measured in the MRE assay, we also included TNF-α. As shown in Figure 4A, we observed 2- to 4-fold differences across individuals in the IC<sub>50</sub> for these cytokines pre-transplant. Interestingly, there were also significant differences between cytokines, with IL-2 having the lowest IC<sub>50</sub> and TNF-α having the greatest. There were also statistically significant, positive correlations across individuals for most of the tested cytokine IC<sub>50</sub> values, suggesting that some individuals were generally more sensitive to tacrolimus than others. Contrary to our hypothesis, we did not observe an increase in mean MRE across subjects with increasing pre-transplant
tacrolimus IC$_{50}$ (Figure 3B). We also did not find positive correlations between IC$_{50}$ and mean residual expression of individual cytokines IL-2 and interferon-γ (not shown).

**DISCUSSION:**

We found that suppressed MRE values were associated with bronchoscopically-detected infections, independent of tacrolimus trough levels. MRE levels increased over time as immunosuppression was weaned and decreased with increasing prednisone doses. Finally, MRE values and pre-transplant sensitivity to tacrolimus varied widely across the cohort, demonstrating the important variations in individual responses immunosuppressive medications.

Previous studies in renal transplantation identified an MRE cutoff of around 30% to discriminate between high and low risk of infection (6). Similarly, we observed here that bronchoscopically-detected infection was rare above an MRE value of 40%. Because of the repeat measure study design, we could not test for an association between MRE and infections not detected at the time of bronchoscopy, including extra-pulmonary infections. These are potentially relevant as cytomegalovirus, for example, has been shown to lower MRE (22).

We did not observe differences in the risk of rejection based on MRE value. While missed study visits and a higher than expected standard deviation for observed MRE values diminished our statistical power somewhat, the available data suggest that MRE values may not be helpful in identifying lung allograft recipients at increased risk for rejection. Interestingly, the ImmunoKnow assay, which has the practical advantage of requiring only one blood sample, also performed better at assessing infection compared with rejection risk (23). Compared to renal allografts, lung allografts may be more antigenic and require greater immunosuppression (24). It is possible that variation in tacrolimus levels within the targets used early after lung transplantation has little impact on the risk of rejection. Consistent with this notion, we previously reported a plateau in the risk of acute rejection as a function of tacrolimus trough beyond a level of 8-10 ng/mL (25). Indeed, highly potent immunosuppression could even drive rejection though the increased innate immune signaling associated with airway infection.

The finding that MRE decreased with increasing prednisone doses suggests that prednisone may act synergistically with tacrolimus in repressing NFAT-dependent cytokines. Our studies on
healthy control samples also demonstrated an effect of steroid dose in the context of the MRE assay. Proinflammatory cytokine gene expression has been shown to increase with low steroid doses and then decrease at the doses typically administered in solid organ transplantation, but these data are the first demonstration of this effect in a context of cytokine suppression by a fixed dose of calcineurin inhibitor (26). The steroid-responsive transcription factor AP-1 also plays an important role in the expression of NFAT-associated genes and so synergistic crosstalk between AP-1 and NFAT signaling pathways may render the MRE assay dependent on other immunosuppressive medications (27). Synergistic effects of steroids and calcineurin inhibitors may limit the specificity of the MRE assay as a measure of tacrolimus-mediated immunosuppression (27, 28).

An important finding of this paper is that immunosuppressive medication sensitivity, whether measured by MRE or by IC$_{50}$, varies substantially between individuals. Because tacrolimus partitions into red blood cells, serum concentrations can be more than 10-fold lower than whole blood levels, so the observed IC$_{50}$ values occur within the range of plasma concentrations that are typical in transplant recipients (29). It is intriguing to consider the potential impacts of variable activation of cytokines as tacrolimus concentrations fluctuate throughout the day. While we hypothesized that high IC$_{50}$ values would predict high average MRE, this was not observed. Although we measured IC$_{50}$ with interferon-$\gamma$, IL-2, and TNF-$\alpha$ production but MRE with interferon-$\gamma$, IL-2, and GM-CSF, it is unlikely that this discrepancy accounted for the lack of correlation, as no correlation was observed for the individual cytokines. Indeed, TNF-$\alpha$ is reportedly more narrowly regulated by NFAT subtypes and thus might be a more potent driver of MRE (30). Beyond static patient factors like genotype-determined tacrolimus sensitivity, a number of clinical factors, including age, medical comorbidities, acute and chronic infections, and tacrolimus pharmacokinetics, could contribute to the observed substantial variation in MRE between individuals.

In conclusion, these data demonstrate the potential clinical utility of MRE measurement in lung allograft recipients to identify subjects at increased risk for infection, as well as its limitations. Interestingly, we found that this assay was dependent on prednisone dose, suggesting an interaction between the tacrolimus and prednisone signaling pathways in modulating NFAT-related gene expression. These studies highlight the inadequacies of current methods for lung transplant immunosuppression monitoring and suggest that strategies to characterize the degree of immunosuppression could be of value in lung transplant recipients.
ACKNOWLEDGEMENTS:
The authors would like to thank Joey Leung and Allison Webber for advice regarding study
design and methodology. We thank Charlene Fong, Chiyo Uchida, Edelyn Bautista, Linda
Nicola, Mary Beier, Daphne Penaflor, Michelle Devaux, Michelle Ramirez, Fredde Foster, David
Prince, AnaMarie Goscila, Mary Heindel, Ivy Sparks, Irene Junejo, Bonnie Slater, Cecilia
Lemieux, Paul Tan, Nelson Mercado, Anna Volfson, Karen Neun, Blake Young, Juliet Zabel help
with collecting study samples.

DISCLOSURES:
Funding: Astellas Pharma Global Development, Inc. primarily funded this investigator-initiated
study, but had no role in data collection, analysis, interpretation, nor approval of the final
manuscript. JRG is also supported by Award Number IK2CX001034 from the Clinical Sciences
Research & Development Service of the VA Office of Research and Development.
Authorship: JRG, JAG, SRH, JPS, and QT designed the research. JRG wrote the paper. TC,
ASW, EM, PS performed the research. JK, SRH, JAG, and JPS recruited subjects and
developed clinical research infrastructure. TC and ASW enrolled subjects. JRG, TC, EM, and
QT conducted data analysis.
The authors of this manuscript have no conflicts of interest to disclose as described by the
American Journal of Transplantation.

Supporting information
Additional Supporting Information may be found online in the supporting information tab for this
article.
- Supplemental Figure 1: Flow diagram of study subject recruitment and sample
  collection.
- Supplemental Figure 2: Comparison of gene expression measurements across
  quantitative PCR devices.
- Supplemental Figure 3: Pharmacokinetic effects on MRE measurements
- Supplemental Table 1: Clinical data for bronchoscopically-determined infection
  cases
- Supplemental Methods: MRE Assay, MRE and Steroid Interaction Assay, and Flow
cytometric measurement of tacrolimus 50% inhibitory concentration (IC$_{50}$)
### Table 1 – Subject Characteristics

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects included, N</td>
<td>44</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>58 (11)</td>
</tr>
<tr>
<td>Male gender, N (%)</td>
<td>34 (77%)</td>
</tr>
<tr>
<td>Transplant type, N (%)</td>
<td></td>
</tr>
<tr>
<td>Double lung</td>
<td>42 (95%)</td>
</tr>
<tr>
<td>Single lung</td>
<td>2 (5%)</td>
</tr>
<tr>
<td>Ethnicity, N (%)</td>
<td></td>
</tr>
<tr>
<td>White, non-Hispanic</td>
<td>32 (73%)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>9 (20%)</td>
</tr>
<tr>
<td>Black</td>
<td>3 (7%)</td>
</tr>
<tr>
<td>Diagnosis group, N (%)</td>
<td></td>
</tr>
<tr>
<td>A – Obstructive</td>
<td>8 (18%)</td>
</tr>
<tr>
<td>B – Pulmonary vascular</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>C – Cystic fibrosis</td>
<td>2 (5%)</td>
</tr>
<tr>
<td>D – Restrictive</td>
<td>33 (75%)</td>
</tr>
</tbody>
</table>
Figure 1: Mean Residual Expression (MRE) values as a function of time post-transplant and tacrolimus trough, prednisone dose, and mycophenolate mofetil dose. MRE increased by 0.35% (95% CI 0.001 – 0.69%, P = 0.049) per week following transplant (A). There was no statistically significant association between MRE and tacrolimus trough value (B, P = 0.11) or mycophenolate mofetil dose (C, P = 0.46), however MRE decreased by 1.7% (95% CI 0.1 – 3.3%, P = 0.04) per mg of daily prednisone dose (D). Local estimated mean values (solid lines) with 95% confidence intervals (dashed lines) were determined by generalized additive modeling.
Figure 2: Ex-vivo MRE as a function of prednisolone level in healthy control subjects. Whole blood from non-immunosuppressed healthy controls (N = 5) was incubated with or without 10 ng/ml tacrolimus and 0, 20, 100, or 200 ng/ml of prednisolone. Grey lines indicate individual subjects. Mean and robust standard errors are shown in black.
Figure 3: Association between MRE and tacrolimus levels and rejection and infection outcomes. MRE is shown stratified by (A) rejection grade and (B) the presence of infection, with bars indicating mean and 95% confidence intervals derived from GEE-adjusted models. Open circles indicate neither infection nor rejection, square symbols indicate rejection, and filled symbols indicate infection. The presence of any type of rejection on biopsy was not associated with MRE (P = 0.74), however mean values for MRE were 20% lower (95% CI 11% – 29%, P <0.001) at the time of infection. The hazard ratios for infection as a function of tacrolimus trough level (C) and MRE (D) are shown, with overall hazard ratios calculated by GEE-adjusted linear models. The hazard ratio for infection was 0.75 (95% CI 0.63 – 0.89) per 10% increase in MRE after adjusting for tacrolimus trough level.
Figure 4: Variability in T cell inhibition by tacrolimus. (A) The concentration of tacrolimus required to reduce stimulated IL-2, Interferon-γ, and TNF-α expression by 50% (IC$_{50}$) was determined for CD4+ and CD8+ T cells isolated pre-transplant from study subjects, where available. Lines indicate individual subjects. Significant heterogeneity was observed between subjects and cytokines, with inhibition IL-2 production requiring the least tacrolimus. The significance of unadjusted paired t-test comparisons between groups are indicated as *, P <0.05; ***, P <0.001. (B) Pre-transplant tacrolimus IC$_{50}$ for all three cytokines is shown as a function of average value of MRE for each subject, with regression lines. There was no significant correlation between IC$_{50}$ and mean MRE for CD4+ or CD8+ T cells.
REFERENCES:

To achieve target enrollment of 50 subjects with at least one sample collected, 66 were approached. After excluding inadequate samples, 44 unique subjects remained. The time requirement of interval blood draws was frequently given as a reason for declining enrollment and for deferring first or second sample collections. There were no statistically significant differences in the rates of infection ($P = 0.18$) or rejection ($P = 0.29$) across these bronchoscopies when stratified by sample inclusion.
Supplemental Figure 2: Comparison of gene expression measurements across quantitative PCR devices. The difference in PCR cycles to reach a threshold concentration (delta CT) between IFN-γ, IL-2, and GM-CSF and the β-actin control is shown for replicate samples measured in the two devices used in the study. (A) Delta CT for the Viia7 device is plotted against delta CT for the Bio-Rad device. Red line shows linear regression fit with 95% confidence intervals ($R^2 = 0.73$). (B) Bland-Altman plot showing difference between devices as a function of the average from the two devices. Red line shows mean difference with 95% confidence intervals, while blue lines show upper and lower limits with 95% confidence intervals. There was a bias of 0.61 (95% CI 0.17 – 1.05) between delta CT values between the two devices. The study data were adjusted to account for this bias between machines.
Supplemental Figure 3: Pharmacokinetic effects on MRE measurements. (A) MRE is shown as a function of the time between tacrolimus dose and the second blood draw. Horizontal lines show the target interval of 90-120 minutes. While some samples were collected slightly out of this target window, we did not observe an association between sample timing an MRE (P = 0.90). (B) MRE is shown as a function of time since the dose taken the previous evening based on subject recall. There was no effect of time between doses on MRE. Local estimated mean values (solid lines) with 95% confidence intervals (dashed lines) were determined by generalized additive modeling.
## Supplemental Table 1: Clinical data for bronchoscopically-determined infection cases

<table>
<thead>
<tr>
<th>Subject ID</th>
<th>BAL Culture Results</th>
<th>Post-Transplant Week</th>
<th>Transbronchial Biopsy Findings</th>
<th>Symptoms</th>
<th>Imaging findings</th>
<th>Treated for infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>020</td>
<td>Few <em>Aspergillus niger</em></td>
<td>11</td>
<td>Not Done</td>
<td>Decrease in FEV1, cough, copious mucous on bronchoscopy</td>
<td>Patchy ground glass</td>
<td>Yes</td>
</tr>
<tr>
<td>029</td>
<td>Rare <em>Aspergillus versicolor</em></td>
<td>13</td>
<td>A0B0</td>
<td>None</td>
<td>Nodules and ground glass opacities</td>
<td>Yes</td>
</tr>
<tr>
<td>029</td>
<td>Moderate <em>Aspergillus fumigatus</em></td>
<td>76</td>
<td>A0B0</td>
<td>None</td>
<td>Moderate air trapping</td>
<td>Yes</td>
</tr>
<tr>
<td>048</td>
<td>Moderate <em>Haemophilus parainfluenzae</em></td>
<td>13</td>
<td>A0B0</td>
<td>None</td>
<td>Mild air trapping</td>
<td>Yes</td>
</tr>
<tr>
<td>167</td>
<td>Rare <em>Aspergillus niger</em></td>
<td>28</td>
<td>A2B0</td>
<td>Cough</td>
<td>Trace effusions</td>
<td>Yes</td>
</tr>
<tr>
<td>167</td>
<td>Moderate <em>Pseudomonas aeruginosa</em></td>
<td>33</td>
<td>A1B0</td>
<td>Cough</td>
<td>Trace effusions</td>
<td>Yes</td>
</tr>
<tr>
<td>264</td>
<td>Numerous <em>Haemophilus parainfluenzae</em></td>
<td>12</td>
<td>A0B0</td>
<td>Cough</td>
<td>Mild air trapping</td>
<td>Yes</td>
</tr>
<tr>
<td>301</td>
<td>Rare <em>Mucorales</em></td>
<td>13</td>
<td>Not Done</td>
<td>Cough and flu-like symptoms</td>
<td>Scattered nodules and mild air trapping</td>
<td>Yes</td>
</tr>
<tr>
<td>331</td>
<td>Moderate <em>Stenotrophomonas maltophilia</em></td>
<td>19</td>
<td>Not Done</td>
<td>Cough</td>
<td>No e/o infection</td>
<td>Yes</td>
</tr>
<tr>
<td>331</td>
<td>Moderate <em>Stenotrophomonas maltophilia</em></td>
<td>23</td>
<td>A0B0</td>
<td>Cough</td>
<td>No e/o infection</td>
<td>Yes</td>
</tr>
<tr>
<td>332</td>
<td>Moderate <em>Stenotrophomonas maltophilia</em></td>
<td>13</td>
<td>A0B0</td>
<td>Cough</td>
<td>Worsening pleural effusions</td>
<td>Yes</td>
</tr>
<tr>
<td>356</td>
<td>Rare <em>Aspergillus spp.</em></td>
<td>10</td>
<td>A0B0</td>
<td>None</td>
<td>No e/o infection</td>
<td>Yes</td>
</tr>
<tr>
<td>371</td>
<td><em>Metapneumovirus</em></td>
<td>8</td>
<td>Not Done</td>
<td>Cough, fatigue</td>
<td>Mild air trapping</td>
<td>Yes (prednisone)</td>
</tr>
<tr>
<td>371</td>
<td>Rare <em>Aspergillus niger</em></td>
<td>13</td>
<td>A0B0</td>
<td>Cough</td>
<td>Not done</td>
<td>Yes</td>
</tr>
<tr>
<td>383</td>
<td>Moderate <em>Aspergillus niger</em></td>
<td>25</td>
<td>A0B0</td>
<td>Cough</td>
<td>No e/o infection</td>
<td>Yes</td>
</tr>
<tr>
<td>397</td>
<td>Moderate <em>Haemophilus parainfluenzae</em></td>
<td>51</td>
<td>A0B0</td>
<td>None</td>
<td>Not done</td>
<td>Yes</td>
</tr>
<tr>
<td>397</td>
<td>Few <em>Haemophilus parainfluenzae</em></td>
<td>78</td>
<td>A0B0</td>
<td>Cough</td>
<td>No e/o infection</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Supplemental Methods

MRE Assay:
Blood was collected in heparinized tubes before and 90-120 min after a scheduled dose of tacrolimus and within one day of a bronchoscopy scheduled for cause, such as suspected infection or rejection, or for surveillance (conducted 2, 3, 6, 12, or 18 months after transplantation per UCSF protocol). If a subject was scheduled for a bronchoscopy the same day, the trough tacrolimus level was drawn during placement of a peripheral venous catheter before bronchoscopy, and tacrolimus was taken following the bronchoscopy as soon as the treating nurse determined that swallowing was safe, again 90-120 minutes before the peak sample blood draw.

In triplicate, 1 ml of blood was combined with 1 ml of Roswell Park Memorial Institute (RPMI, #61870127, Thermo Fisher Scientific, Waltham, MA) medium containing 10% Human AB serum (#HS-25, Omega Scientific, Tarzana, CA) and 1% penicillin/streptomycin (#54140, Thermo Fisher) for 3 h at 37°C. Stimulated wells included 100 ng/ml phorbol 12-myristate 13-acetate (PMA, #P1585, Sigma-Aldrich, St. Louis, MO) and 5 ug/ml ionomycin (#I9657, Sigma-Aldrich) with the RPMI-based medium during incubation. Red blood cells were lysed with RBC lysing buffer (#555899, BD Biosciences, Franklin Lakes, NJ) prior to mRNA isolation using the High Pure RNA Isolation Kit (#11 828 665 001, Roche, Indianapolis, IN). RNA quality was assessed using a NanoDrop Spectrophotometer (#ND-2000, Thermo Fisher). cDNA was synthesized using the SuperScript III First Strand Protocol (#18080-051, Thermo Fisher). Quantitative PCR was performed according to the RT2 qPCR Primer Assay Protocol (Qiagen, Germantown, MD) using a Bio-Rad CFX96 (Hercules, CA) or Applied Biosystem Viia7 (Thermo Fisher) device. Delta CT values were corrected for the bias between the two devices as determined in Supplemental Figure 2B. We used Qiagen primers for β-actin, IFN-γ, IL-2 and GM-CSF (#PPH00073E-200, PPH00380B-200, PPH00172B-200, and PPH00576B-200). The MRE was calculated as:

$$\frac{100}{3} \cdot \sum_{x \in \{IL-2, GM-CSF, IFN\}} 2^{\left(\frac{Ct_{x, post-dose} - Ct_{actin, post-dose}}{\Delta Ct_{actin}} - \frac{Ct_{x, pre-dose} - Ct_{actin, pre-dose}}{\Delta Ct_{actin}}\right)}$$

where Ct denotes cycle threshold for stimulated whole blood samples assayed with the given primer, x. MRE values > 140% were excluded, as these were associated with low RNA quality and quantity.

MRE and Steroid Interaction Assay
Non-transplant control samples were incubated in RPMI media containing serum, 0 or 10 ng/ml, and 0, 20, 100, or 200 ng/ml of prednisone at 37°C and 5% CO2 for 90 min prior to PMA/ionomycin stimulation as described above.

**Flow cytometric measurement of tacrolimus 50% inhibitory concentration (IC50)**

Cryopreserved PBMC samples taken from recipients at the time of transplant were thawed and rested overnight in RPMI with 10% Human AB serum, 1% penicillin/streptomycin, and 1% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 25-060-Cl, Corning, Manassas, VA). The following day, tacrolimus (Alfa Aesar 104987-11-3, Tewksbury, MA) was serially diluted to concentrations of 30, 10, 1, 0.3, 0.1, 0.01, and 0 ng/ml. Each concentration was incubated with the PBMC sample resuspended in RPMI with 10% Fetal Bovine Serum for 30 min. Samples were then stimulated with 50 ng/ml PMA, 2.5 ug/ml ionomycin, and 10 ug/ml brefeldin A (BFA, # B6542, Sigma-Aldrich) for 5 h. After stimulation, cells were surface stained with FITC anti-CD8 (#347313, BD Bioscience), PECy7 anti-CD4 (#557852, BD Bioscience), APCy7 anti-CD3 (#344818, BioLegend, San Diego, CA), and e506 viability (#65-0863-18, Thermo Fisher). Cytokine staining with PE-anti-IFN-γ (#559327, BD Bioscience), APC anti-IL2 (#554567, BD Bioscience), and V450 anti-TNF (#561311, BD Bioscience) was performed after fixation and permeabilization using BD Cytofix/Cytoperm (#544723, BD Bioscience). Data acquisition was performed on the Navios Flow Cytometer and gated using Kaluza analysis software (version 1.2, Beckman Coulter, Brea, CA). IC50 was determined from percent of CD4+ or CD8+ T cells producing cytokine, using the inflection point of an N-parameter logistic regression curve fit derived with the R nplr package (Commo F, Bot BM. nplr: N-Parameter Logistic Regression. 0.1-7 ed2016).